NanoViricides (NYSEMKT:NNVC) has signed
a Memorandum of Understanding (MoU) with respect to anti-viral
treatments for coronavirus-derived human infections (the “Field”) with
privately held TheraCour Pharma, Inc.
The MoU specifically provides a limited, exclusive
license to all research and development in the Field for further
R&D purposes towards human clinical trials.
NanoViricides intends to retain an independent
consultant for the evaluation of assets in order to develop the full
license agreement.
Along with working on drug development to treat
COVID-19 infection, the company had previously engaged in limited
R&D for the treatment of MERS coronavirus during 2014.
The company has found that the broad-spectrum
anti-coronavirus drug candidates that it is developing were several
times more effective than favirpravir in cell culture assays against two
different coronaviruses, namely hCoV-229E and hCoV-NL63.
NanoViricides has also found that these drug
candidates showed strong effectiveness in an animal model of human
coronavirus disease, potentially superior to remdesivir, although no
firm conclusions to that effect can be drawn.
https://seekingalpha.com/news/3581399-nanoviricides-teams-up-theracour-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.